With all of this in mind, let’s take a glance at the new action regarding Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Heading into Q4, a total of 88 of the hedge funds tracked by Insider Monkey held long positions in this …
INSIDER MONKEY · 11/21/2015
hedge funds
In-depth coverage >
VRX) does not seem to catch a break. On Tuesday, it was revealed that the company’s female libido drug, acquired in August from a $1 billion takeover of its maker, is entirely failing in the market. Volatile as it is … · 11/19/2015
The stock is now at $231. Note: In August, Berkshire Hathaway agreed to buy PCP for $235 per share cash. Valeant Pharmaceuticals (NYSE:VRX): VRX is Ruane, Cunniff & Goldfarb's largest stock position at 31.06% …
Seeking Alpha · 1 day ago
However, the stock trades at a discount to competitors, and may have upside moving forward, said trader Karen Finerman. Tim Seymour is long AAPL, BAC, CLF, DIS, F, FCX, GE, GM, GOOGL, INTC, JCP, JPM, KO …
CNBC · 11/25/2015
discount stocks
William Ackman's Pershing Square Capital Management LP on Monday disclosed an increased 9.9% stake in Valeant Pharmaceuticals International Inc. (VRX). Mr. Ackman has vigorously ... saying the company's …
NASDAQ · 11/24/2015
Hot Stocks
It is no surprise therefore that investors are looking for a drug company with a new business model, and that may explain the meteoric rise of Valeant (VRX) over the five years ... that they had never liked. The stock price dropped below $80 per share ...
Wall Street Pit · ByAswath Damodaran · 11/17/2015
I see (VRX <equity> OV on the Bloomberg terminal ... Also, it is not entirely a bad thing for Ackman to push Valeant's stock price up, since he already owned so much of it. But better to push it up after his buying than … · 11/24/2015
Bill Ackman
The Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX) stock price has dropped 44% year to date and nearly 80% over the last three months. While some are saying VRX stock has now become undervalued, Money Morning Global Credit Strategist Michael …
Money Morning · ByDiane Alter · 11/6/2015
VRX) securities between February 28, 2014 and October 21, 2015 inclusive (the “Class Period”). Investors who suffered losses of over $500,000 on their investment in Valeant securities are encouraged to contact the Law Offices of Howard G. Smith to ...
Financial Content · 11/20/2015
Law Offices
TORONTO (Reuters) - Canada's main stock index edged up on Thursday ... The most influential gainer on the index was Valeant Pharmaceuticals International Inc VRX.TO, which rose 1.6 percent to C$117.16. The overall healthcare group climbed 1.6 …
Reuters · 11/26/2015
energy stocks

Valeant Pharmaceuticals

Valeant Pharmaceuticals International, Inc. is a publicly traded multinational specialty drugs company based in Laval, Quebec, Canada. The co…
Valeant Pharmaceuticals International, Inc. is a publicly traded multinational specialty drugs company based in Laval, Quebec, Canada. The company focuses on purchasing the rights to older generic drugs and raising prices, sometimes to hundreds or thousands of dollars per pill. Valeant's main drug markets include neurology, dermatology and infectious disease with several drugs in late-stage clinical trials and several currently on the market. In addition, Valeant has a portfolio of more than 500 products from its prior history as a group of specialty chemical and radiochemical research, development and supply companies with a history stretching back to the 1960s. Valeant's strategy of exponential price increases on lifesaving medicines has been described by Berkshire Hathaway Vice Chariman Charlie Munger as "deeply immoral" and "similar to the worst abuses in for-profit education."
Data from: Wikipedia